NCT00924703已完成2 期
Long-term Extension of a Phase 2, Open-Label Dose-Finding Study to Evaluate the Safety, Efficacy, and Tolerability of Multiple Subcutaneous Doses of rAvPAL-PEG in Subjects With PKU
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 68
- 试验地点
- 14
- 主要终点
- Change From Baseline in the Blood Phenylalanine (Phe) Concentration
研究概览
简要总结
This study is an extension of previous rAvPAL-PEG studies. Administration of rAvPAL-PEG will be continued to assess whether long-term dosing of rAvPAL-PEG is safe and can maintain reduced blood Phe concentrations in PKU subjects.
详细描述
PAL-003 is designed to evaluate long-term treatment of subjects who are continuing to take rAvPAL-PEG. Subjects'previous rAvPAL-PEG dosing will continue in PAL-003. In PAL-003, each subject's dose will be adjusted as needed to attain or maintain blood Phe concentrations of 60-600 µmol/L. rAvPAL-PEG dose will be based on either a subject's weight or will be a fixed dose (subjects who have maintained blood Phe levels to 60-600 µmol/L for at least 2 consecutive weeks and who have maintained a stable rAvPAL-PEG dose for at least 2 consecutive weeks). Doses will be evaluated on an individual basis.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 16 Years 至 55 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Must have completed participation in previous rAvPAL-PEG studies.
- •Willing and able to provide written, signed informed consent, or, in the case of participants under the age of 18, provide written assent (if required) and written informed consent by a parent or legal guardian, after the nature of the study has been explained, and prior to any research-related procedures.
- •Willing and able to comply with all study procedures.
- •Females of childbearing potential must have a negative pregnancy test at Screening and be willing to have additional pregnancy tests during the study. Females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to Screening, or who have had total hysterectomy.
- •Sexually active subjects must be willing to use an acceptable method of contraception while participating in the study.
- •Maintained a stable diet.
- •In generally good health as evidenced by physical examination, clinical laboratory evaluations (hematology, chemistry, and urinalysis), and electrocardiogram (ECG) at Screening.
排除标准
- •Use of any investigational product (with the exception of rAvPAL-PEG) or investigational medical device within 30 days prior to Screening, or requirement for any investigational agent prior to completion of all scheduled study assessments.
- •Use of any medication that is intended to treat PKU within 14 days prior to the administration of study drug.
- •Use or planned use of any injectable drugs containing PEG (other than rAvPAL-PEG), including Depo-Provera during study participation.
- •A prior reaction that included systemic symptoms (eg, generalized hives, respiratory or gastrointestinal problems, hypotension, angioedema, anaphylaxis) to rAvPAL-PEG or a PEG-containing product.
- •Pregnant or breastfeeding at Screening or planning to become pregnant (self or partner) or to breastfeed at any time during the study.Concurrent disease or condition that would interfere with study participation or safety (eg, history or presence of clinically significant cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurological, oncologic, or psychiatric disease).
- •Any condition that, in the view of the PI, places the subject at high risk of poor treatment compliance or of not completing the study.
- •Known hypersensitivity to rAvPAL-PEG or its excipients, including hypersensitivity reactions that necessitated early termination from previous rAvPAL-PEG studies.
- •Alanine aminotransferase (ALT) concentration > 2 times the upper limit of normal.
- •Creatinine > 1.5 times the upper limit of normal.
研究组 & 干预措施
rAvPAL-PEG
Experimental
rAvPAL-PEG in varying doses dependent on safety and efficacy.
干预措施: rAvPAL-PEG (Drug)
结局指标
主要结局
Change From Baseline in the Blood Phenylalanine (Phe) Concentration
时间窗: At Baseline and Change from Baseline to Week 48, Week 96, Week 144, Week 216, and Week 240
Blood Phe Concentration (Change from Baseline) and Daily Dose in PAL-003 Subjects by Disposition (PAL-003 Population)
次要结局
- Pharmacokinetics-Plasma Pegvaliase Concentration(At Baseline, Week 48, Week 96, Week 144, Week 216 and Week 240)
- Number of Subjects With Treatment Emergent Adverse Events (TEAEs)(Up to 109 months.)
- Percentage of Participants With Positive PEG IgG Antibody(At Baseline and Change from Baseline to Week 24, Week 52, Week 104 and Week 156)
- Percentage of Participants With Positive PAL IgG Antibody(At Baseline and Change from Baseline to Week 24, Week 52, Week 104 and Week 156)
研究者
研究点 (14)
Loading locations...
相似试验
终止
2 期
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)AcromegalyNCT04261712Crinetics Pharmaceuticals Inc.43
终止
2 期
An Extension Study of GDC-0853 in Participants With Moderate to Severe Active Systemic Lupus ErythematosusLupus Erythematosus, SystemicNCT03407482Genentech, Inc.160
已完成
2 期
Open-Label Extension Study of Patients Previously Enrolled in Study CIN-107-124HypertensionNCT05459688AstraZeneca175
终止
2 期
A Phase 2, Open-Label, Extension Study to Evaluate Long Term Safety and Clinical Activity of Briquilimab in Participants From Jasper-Sponsored Chronic Urticaria TrialsUrticaria ChronicNCT06736262Jasper Therapeutics, Inc.67
进行中（未招募）
2 期
Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)FSHDFSHD1FSHD2FMDFMD2Fascioscapulohumeral Muscular DystrophyFascioscapulohumeral Muscular Dystrophy Type 1Fascioscapulohumeral Muscular Dystrophy Type 2Dystrophies, Facioscapulohumeral MuscularDystrophy, Facioscapulohumeral MuscularFacioscapulohumeral Muscular Dystrophy 1Facioscapulohumeral Muscular Dystrophy 2Facio-Scapulo-Humeral DystrophyAtrophy, FacioscapulohumeralAtrophies, FacioscapulohumeralFacioscapulohumeral AtrophyMuscular DystrophiesMuscular Dystrophy, FacioscapulohumeralFSH Muscular DystrophyLandouzy Dejerine DystrophyLandouzy-Dejerine Muscular DystrophyDystrophies, Landouzy-DejerineDystrophy, Landouzy-DejerineLandouzy-Dejerine SyndromeMuscular Dystrophy, Landouzy DejerineFSHProgressive Muscular DystrophyNCT06547216Avidity Biosciences, Inc.84